Lumos Pharma, Inc.
LUMODelisted Dec 12, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001126234
Lumos Pharma, Inc. was delisted on Dec 12, 2024; its insiders filed their last Form 4 on Dec 13, 2024; 29 institutions reported holding it in 13F filings for Q3 2024, worth $8.08M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 29
- Q3 2024, −6 vs. previous quarter
- 13F value
- $8.08M
- Reported value at the end of Q3 2024
- Superinvestors holding
- 0
- At the end of Q3 2024
Superinvestors holding LUMO, Q3 2024
No superinvestor reported holding LUMO at the end of Q3 2024.
Latest insider trades
Open-market purchases and sales by Lumos Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2024 (view filing) | Aug 6 | Same day | McKew John C.Chief Scientific Officer | SSale | −3.41K | $1.89 | −$6.44K | −21.2%12.7K after | 10b5-1 |
| Apr 3, 2024 (view filing) | Apr 3 | Same day | McKew John C.Chief Scientific Officer | SSale | −2.21K | $2.78 | −$6.15K | −11.4%17.2K after | 10b5-1 |
| Feb 7, 2024 (view filing) | Feb 6 | 1 day | McKew John C.Chief Scientific Officer | SSale | −438 | $3.03 | −$1.33K | −2.3%18.4K after | 10b5-1 |
| Aug 3, 2023 (view filing) | Aug 2 | 1 day | McKew John C.Chief Scientific Officer | SSale | −3.41K | $3.21 | −$10.9K | −15.4%18.7K after | 10b5-1 |
| Apr 4, 2023 (view filing) | Apr 4 | Same day | McKew John C.Chief Scientific Officer | SSale | −2.21K | $3.27 | −$7.24K | −8.7%23.2K after | 10b5-1 |
| Feb 3, 2023 (view filing) | Feb 2 | 1 day | McKew John C.Chief Scientific Officer | SSale | −439 | $3.53 | −$1.55K | −1.6%26.5K after | |
| Nov 18, 2022 (view filing) | Nov 16 | 2 days | McCracken Joseph SDirector | PPurchase | +4.00K | $5.03 | +$20.1K | +34.1%15.7K after | |
| Sep 23, 2022 (view filing) | Sep 21-23 | 2 days | Hawkins Richard JChief Executive Officer | PPurchase | +2.42K | $8.84 | +$21.4K | +118.3%4.47K after | 2 lots |
| Sep 21, 2022 (view filing) | Sep 19-20 | 2 days | Hawkins Richard JChief Executive Officer | PPurchase | +2.05K | $8.72 | +$17.9K | New position2.05K after | 2 lots |
| Aug 26, 2022 (view filing) | Aug 25 | 1 day | Raffin Thomas A.Director | PPurchase | +1.15K | $8.46 | +$9.73K | +13.9%9.41K after |
Top 10 13F holders, Q3 2024
The largest institutional positions in Lumos Pharma, Inc. at the end of Q3 2024; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Private Advisor Group, LLC | 744,513 | $2.88M | 0.02% | +714,500+2,380.6% | Added |
| Goldman Sachs Group Inc | 362,198 | $1.40M | 0.00% | −44,413−10.9% | Reduced |
| Vanguard Group Inc | 244,082 | $944.6K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 213,814 | $827.5K | 0.00% | −2,000−0.9% | Reduced |
| Jefferies Financial Group Inc. | 120,651 | $466.9K | 0.01% | 00.0% | Unchanged |
| Greenwich Wealth Management LLC | 76,341 | $295.0K | 0.02% | 00.0% | Unchanged |
| Wells Fargo & Company | 64,981 | $251.5K | 0.00% | −350,000−84.3% | Reduced |
| Geode Capital Management, LLC | 55,148 | $213.5K | 0.00% | +4,421+8.7% | Added |
| BlackRock, Inc. | 39,825 | $154.1K | 0.00% | +39,825 | New |
| Lion Point Capital, LP | 39,589 | $153.2K | 0.61% | −51,205−56.4% | Reduced |